Abstract
A Stanford team has identified a compound that blocked growth of renal cell carcinomas in mice by inhibiting a metabolic pathway unique to the tumors. The GLUT1 inhibitor has been exclusively licensed by Ruga Corp., which is optimizing the compound and hopes to be in the clinic next year.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.